{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:47:09Z","timestamp":1794570429072,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T00:00:00Z","timestamp":1244678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1745-6215-10-39","type":"journal-article","created":{"date-parts":[[2009,6,30]],"date-time":"2009-06-30T18:22:16Z","timestamp":1246386136000},"source":"Crossref","is-referenced-by-count":130,"title":["Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial"],"prefix":"10.1186","volume":"10","author":[{"given":"Matthew R","family":"Sydes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh KB","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel W","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P","family":"Dearnaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Royston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,6,11]]},"reference":[{"issue":"14","key":"327_CR1","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/sim.1430","volume":"22","author":"P Royston","year":"2003","unstructured":"Royston P, Parmar MK, Qian W: Novel designs for multi-arm clinical trials with survival outcomes with an application in ovarian cancer. Stat Med. 2003, 22 (14): 2239-2256. 10.1002\/sim.1430.","journal-title":"Stat Med"},{"issue":"4","key":"327_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/bimj.200510231","volume":"48","author":"H Schmidli","year":"2006","unstructured":"Schmidli H, Bretz F, Racine A, Maurer W: Confirmatory seamless phase II\/III clinical trials with hypotheses selection at interim: applications and practical considerations. Biom J. 2006, 48 (4): 635-643. 10.1002\/bimj.200510231.","journal-title":"Biom J"},{"issue":"17","key":"327_CR3","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/jnci\/djn267","volume":"100","author":"MKB Parmar","year":"2008","unstructured":"Parmar MKB, Barthel F, Sydes M, Langley R, Kaplan R, Eisenhauer E: Speeding up the Evaluation of New Agents in Cancer. J Natl Cancer Inst. 2008, 100 (17): 1204-1214. 10.1093\/jnci\/djn267.","journal-title":"J Natl Cancer Inst"},{"key":"327_CR4","volume-title":"Proc ASCO Prostate Cancer Symposium","author":"N James","year":"2007","unstructured":"James N, Mason M, Sydes M, Sanders K, Dearnaley D, Anderson J: Successful recruitment to the feasibility stage of STAMPEDE: A multi-arm, multi-stage phase II\/III trial in high risk prostate cancer (ISRCTN78818544). Proc ASCO Prostate Cancer Symposium. 2007"},{"issue":"4","key":"327_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1464-410X.2008.08034.x","volume":"103","author":"ND James","year":"2009","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J: Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int. 2009, 103 (4): 464-469. 10.1111\/j.1464-410X.2008.08034.x.","journal-title":"BJU Int"},{"issue":"8","key":"327_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.clon.2008.07.002","volume":"20","author":"ND James","year":"2008","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J: STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer \u2013 A Multi-Arm Multi-Stage Randomised Controlled Trial. Clinical Oncology. 2008, 20 (8): 577-581. 10.1016\/j.clon.2008.07.002.","journal-title":"Clinical Oncology"},{"key":"327_CR7","unstructured":"STAMPEDE trial website. 2009, http:\/\/www.stampedetrial.org"},{"issue":"4","key":"327_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","volume":"8","author":"RL Prentice","year":"1989","unstructured":"Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989, 8 (4): 431-440. 10.1002\/sim.4780080407.","journal-title":"Stat Med"},{"issue":"10","key":"327_CR9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ejca.2006.02.011","volume":"42","author":"L Collette","year":"2006","unstructured":"Collette L, Burzykowski T, Schroder FH: Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer. 2006, 42 (10): 1344-1350. 10.1016\/j.ejca.2006.02.011.","journal-title":"Eur J Cancer"},{"issue":"15","key":"327_CR10","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004, 351 (15): 1502-1512. 10.1056\/NEJMoa040720.","journal-title":"N Engl J Med"},{"issue":"15","key":"327_CR11","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004, 351 (15): 1513-1520. 10.1056\/NEJMoa041318.","journal-title":"N Engl J Med"},{"issue":"May 20 suppl","key":"327_CR12","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/jco.2008.26.15_suppl.lba4","volume":"26","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. J Clin Oncol. 2008, 26 (May 20 suppl): LBA4-","journal-title":"J Clin Oncol"},{"issue":"6","key":"327_CR13","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","volume":"7","author":"EM Messing","year":"2006","unstructured":"Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006, 7 (6): 472-479. 10.1016\/S1470-2045(06)70700-8.","journal-title":"Lancet Oncol"},{"issue":"9660","key":"327_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","volume":"373","author":"A Widmark","year":"2009","unstructured":"Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3): an open randomised phase III trial. Lancet. 2009, 373 (9660): 301-308. 10.1016\/S0140-6736(08)61815-2.","journal-title":"Lancet"},{"issue":"19","key":"327_CR15","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1001\/jama.296.19.2329","volume":"296","author":"IM Thompson Jr","year":"2006","unstructured":"Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006, 296 (19): 2329-2335. 10.1001\/jama.296.19.2329.","journal-title":"JAMA"},{"issue":"12","key":"327_CR16","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008, 26 (12): 1987-1992. 10.1200\/JCO.2007.10.8407.","journal-title":"J Clin Oncol"},{"issue":"33","key":"327_CR17","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1200\/JCO.2007.11.8836","volume":"25","author":"M Buyse","year":"2007","unstructured":"Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol. 2007, 25 (33): 5218-5224. 10.1200\/JCO.2007.11.8836.","journal-title":"J Clin Oncol"},{"issue":"11","key":"327_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.bjc.6602858","volume":"93","author":"A Hackshaw","year":"2005","unstructured":"Hackshaw A, Knight A, Barrett-Lee P, Leonard R: Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer. 2005, 93 (11): 1215-1221. 10.1038\/sj.bjc.6602858.","journal-title":"Br J Cancer"},{"issue":"10","key":"327_CR19","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.bjc.6604759","volume":"99","author":"B Sherrill","year":"2008","unstructured":"Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M: Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer. 2008, 99 (10): 1572-1578. 10.1038\/sj.bjc.6604759.","journal-title":"Br J Cancer"},{"issue":"1","key":"327_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.ju.0000129051.81608.d8","volume":"172","author":"MJ Shulman","year":"2004","unstructured":"Shulman MJ, Benaim EA: The natural history of androgen independent prostate cancer. J Urol. 2004, 172 (1): 141-145. 10.1097\/01.ju.0000129051.81608.d8.","journal-title":"J Urol"},{"issue":"7","key":"327_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1464-410X.2005.05798.x","volume":"96","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Dahut WL, Steinberg SM, Figg WD, Tarassoff C, Arlen P: A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int. 2005, 96 (7): 985-989. 10.1111\/j.1464-410X.2005.05798.x.","journal-title":"BJU Int"},{"issue":"19","key":"327_CR22","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1200\/JCO.2002.11.021","volume":"20","author":"O Smaletz","year":"2002","unstructured":"Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002, 20 (19): 3972-3982. 10.1200\/JCO.2002.11.021.","journal-title":"J Clin Oncol"},{"issue":"15","key":"327_CR23","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","volume":"339","author":"MA Eisenberger","year":"1998","unstructured":"Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998, 339 (15): 1036-1042. 10.1056\/NEJM199810083391504.","journal-title":"N Engl J Med"},{"issue":"8951","key":"327_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","volume":"345","author":"ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","year":"1995","unstructured":"ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995, 345 (8951): 669-685. 10.1016\/S0140-6736(95)90865-X.","journal-title":"Lancet"},{"issue":"7","key":"327_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta9070","volume":"9","author":"A Grant","year":"2005","unstructured":"Grant A, Altman D, Babiker AB, Campbell M, Clemens F, Darbyshire J: Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005, 9 (7): 1-238.","journal-title":"Health Technol Assess"},{"issue":"9460","key":"327_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S0140-6736(05)70939-9","volume":"365","author":"DAMOCLES study group","year":"2005","unstructured":"DAMOCLES study group: A proposed charter for clinical trial Data Monitoring Committees: helping them to do their job well. Lancet. 2005, 365 (9460): 711-722.","journal-title":"Lancet"},{"issue":"3","key":"327_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jclinepi.2007.07.016","volume":"61","author":"D Bassler","year":"2008","unstructured":"Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G: Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008, 61 (3): 241-246. 10.1016\/j.jclinepi.2007.07.016.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"327_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jclinepi.2007.08.002","volume":"61","author":"MR Sydes","year":"2008","unstructured":"Sydes MR, Parmar MKB: Interim monitoring of efficacy data is important and appropriate. Journal of Clinical Epidemiology. 2008, 61 (3): 203-204. 10.1016\/j.jclinepi.2007.08.002.","journal-title":"Journal of Clinical Epidemiology"},{"key":"327_CR29","doi-asserted-by":"crossref","unstructured":"Bookman M: GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with Gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006, 24 (18S Suppl):","DOI":"10.1200\/jco.2006.24.18_suppl.5002"},{"issue":"9582","key":"327_CR30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(07)61087-3","volume":"370","author":"MT Seymour","year":"2007","unstructured":"Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007, 370 (9582): 143-152. 10.1016\/S0140-6736(07)61087-3.","journal-title":"Lancet"},{"key":"327_CR31","volume-title":"National Research Ethics Service","author":"National Patient Safety Agency","year":"2008","unstructured":"National Patient Safety Agency: National Research Ethics Service. 2008, http:\/\/www.nres.npsa.nhs.uk\/"},{"issue":"8","key":"327_CR32","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","volume":"84","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Coleman RE, Shipman CM, Rostami H, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84 (8): 1126-1134. 10.1054\/bjoc.2001.1727.","journal-title":"Br J Cancer"},{"key":"327_CR33","unstructured":"ICON6 trial website. 2008, http:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00544973?term=icon6&rank=1"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-10-39\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-10-39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-10-39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-10-39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T03:55:30Z","timestamp":1589946930000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-10-39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-10-39","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,11]]},"article-number":"39"}}